FSTX

F-star Therapeutics Inc

NASDAQ

Add Alert

FSTX

F-star Therapeutics Inc

NASDAQ

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

DK11

12/21/22 11:18 AM

Post #13

Re: #12: @DK11 - https://www.sec.gov/Archives/edgar/data/1566373/000119312522309497/d427731dsc14d

https://www.sec.gov/Archives/edgar/data/1566373/000119312522309497/d427731dsc14d9a.htm
And last one I hope. Lol....

DK11

12/21/22 11:17 AM

Post #12

https://www.sec.gov/Archives/edgar/data/1566373/000119312522309497/d427731dsc14d9a.htm
Here is more information on this.

DK11

12/21/22 11:02 AM

Post #11

https://www.sec.gov/Archives/edgar/data/1566373/000119312522309500/d439272d8k.htm
Looks like good news to me

subslover

06/23/22 10:44 AM

Post #10

Re: #9: @rhopton - someone has been hitting the sell button for

invoX Pharma to Acquire F-Star Therapeutics (FSTX) for $7.12 Per Share
https://www.streetinsider.com/Corporate+News/invoX+Pharma+to+Acquire+F-Star+Therapeutics+%28FSTX%29+for+%247.12+Per+Share/20245945.html

rhopton

10/27/21 2:32 PM

Post #9

someone has been hitting the sell button for 5 days straight, this is getting ridiculous that it can't move on major news like that, but these other stocks move 2 to 3 hundred percent on nothing

maximumgriff Free

10/20/21 10:08 AM

Post #8

Re: #7: @Docstemcell2020 - Let's go Brandon! FJB

FJB!!!

Docstemcell2020 Free

10/20/21 9:07 AM

Post #7

Let's go Brandon! FJB

maximumgriff Free

10/20/21 8:46 AM

Post #6

Re: #4: @crudeoil24 - F-star Therapeutics Reports License Deal With J&J's Janssen

Kinda crazy this hasn’t taken off with this mega license deal

maximumgriff Free

10/20/21 8:23 AM

Post #5

Re: #4: @crudeoil24 - F-star Therapeutics Reports License Deal With J&J's Janssen

Big news

crudeoil24 PremiumMember

10/20/21 8:14 AM

Post #4

F-star Therapeutics Reports License Deal With J&J's Janssen To Develop, Commercialize Multiple Next Gen Bispecific Antibody Therapeutics; Co. To Receive Upfront Fees Of $17.5M, Near-Term Fees, Milestones Up To $1.35B
8:04 am ET October 20, 2021 (Benzinga) Print
F-star Therapeutics, Ltd. (NASDAQ:FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that it has entered into a license and collaboration agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by Johnson & Johnson Innovation.

Under the terms of the agreement, F-star will grant Janssen a worldwide, exclusive royalty-bearing license to research, develop, and commercialize up to five novel bispecific antibodies directed to Janssen therapeutic targets using F-star’s proprietary Fcab™ and mAb2™ platforms. Janssen will be responsible for all research, development, and commercialization activities under the agreement.

Neil Brewis, Ph.D., Chief Scientific Officer of F-star said, “We are pleased to collaborate with Janssen and leverage the science of F-star’s proprietary tetravalent bispecific technology. Beyond our proprietary pipeline, we believe there is broad potential for our mAb2 platform to produce multiple next-generation bispecific antibody therapeutics.”

Under the terms of the agreement F-star is entitled to receive upfront fees of $17.5 million, near-term fees and potential further milestones of up to $1.35 billion. F-star is also eligible to receive potential tiered mid-single digit royalties on annual net sales.